<DOC>
	<DOCNO>NCT02553226</DOCNO>
	<brief_summary>Background : The propose study investigate effect Syntocinon® ( synthetic oxytocin ) induce labour . The hypothesis study active phase labour commence , Syntocinon® discontinue labour process continue . Design : Double-blind randomise control multicentre trial Setting : Aarhus University Hospital , Denmark Regional Hospital Randers , Denmark Population : 1200 woman ( 600 group ) stimulate latent phase labour oxytocin induction Methods : The Syntocinon® infusion replace either continuous isotonic saline ( placebo ) Syntocinon® infusion ( control group ) , active phase labour reach . Main outcome measure : Caesarean section ( primary outcome ) , tachysystole , neonatal asphyxia , birth experience Perspective : Syntocinon® list high-alert medication associate complication mother child labour . Reducing duration stimulation labour may lower number asphyxial sequelae number caesarean section .</brief_summary>
	<brief_title>Continued Versus Discontinued Oxytocin Stimulation Labour</brief_title>
	<detailed_description>Randomisation : When orificium ≥6 cm , regular painful contraction ( ≥3 per 10 minute ) rupture membrane participant randomise 1:1 ratio either control ( continued Syntocinon® ) intervention ( discontinue Syntocinon® ) group use Internet-based randomisation programme . The randomisation perform woman consent participation . Written consent give commencement Syntocinon® infusion , provide woman previously receive sufficient information give properly inform consent . Random block-sizes 8 use , participant stratify site ( Aarhus University Hospital , Randers Regional Hospital , Aalborg University hospital , Sygehus Lillebælt Kolding ) , parity ( nulliparous parous ) indication Syntocinon® infusion ( induction induction due premature rupture membrane ) . The randomisation number correspond number project medicine ( ampoule ) . The personnel delivery ward administer ampoule accord exist guideline concern medicine administration Oxytocin stimulation protocol : Existing national procedure prior stimulation follow , include use exist checklist . No examination do prior inclusion stimulation , blood sample ECG identify e.g . unknown QT-syndrome perform never perform standard procedure prior induction . Latent phase : Stimulation give accord national DSOG guidelines7 . Initially 20 ml/hour 10 IE Syntocinon® dilute 1000 ml 0,9 % NaCl . The dose rate increase every 20 minute 20 ml/hour appropriate uterine activity 3-5 contraction per 10 minute achieve . The maximum allow dose rate 180 ml/hour induction labour . Active phase : The woman include study , active phase labour establish ( cervical dilatation ≥ 6 cm , ≥3 contraction per 10 minute , rupture membrane ) . Randomisation perform , infusion replace trial solution , either Syntocinon® concentration , placebo infusion contain Syntocinon® : 1 . Control group ; 10 IE Syntocinon® dilute 1000 ml 0,9 % NaCl infusion 2 . Intervention group ; 1ml 0,9 % NaCl dilute 1000ml 0,9 % NaCl infusion . The infusion continue achieve uterine activity 3-5 contraction per 10 minute . Maximum allow dose 180 ml/hour induction . The procedure administration trial solution identical exist procedure . Complications : The infusion reduce discontinue point labour , follow occur : - Hyperstimulation ( &gt; 5 contraction per 10 minute non-reassuring CTG13 ) . A management algorithm situation make . - Uterine contraction last 2 minute - Non-reassuring CTG ( recurrent variable deceleration , fetal tachycardia bradycardia , minimal absent baseline variability , late deceleration ) - Suspicion uterine rupture These condition manage accord guideline local delivery ward . Dystocia : If failure progress , define less two cm dilation 4 hour despite apparently adequate contraction and/or maximal infusion rate ( Syntocinon® placebo ) , project medicine replace open-labelled Syntocinon® infusion . Stimulation give accord national DSOG guidelines7 . Initially 20 ml/hour 10 IE Syntocinon® dilute 1000 ml 0,9 % NaCl . The dose rate increase every 20 minute 20 ml/hour appropriate uterine activity 3-5 contraction per 10 minute achieve . The maximum allow dose rate is180 ml/hour induction . Woman receive open-labelled Syntocinon® infusion 4 hour continuous failure progress : Consider caesarean section . Unconcealment The primary investigator nominate deputy time able break randomisation code reveal allocation group , need . The Internet Based Randomisation Programme provide primary investigator nominate deputy possibility . ( A 24/7 availability allocation group thereby provide ) . Side effect risk : Persistent failure progress expect 8-46 % participant placebo group versus 3-17 % control group . 3 4 5 6 Based data pilot study , risk caesarean section expect 15 % placebo group versus 22 % control group . According pilot study previous study 3 4 5 6 , maternal neonatal complication placebo group expect low control group . All participant monitor continuous electronic fetal heart rate monitor labour detect complication uterine tachysystole non-reassuring/pathological fetal heart rate , accordance national guideline . The personnel delivery ward responsible register adverse reaction adverse event . Following adverse reaction event register immediately electronic medical journal patient : - Cesarean delivery - Postpartum hemorrhage &gt; 500 ml - Manual placenta removal - Rupture anale sphincter - Urine retention - Neonatal : pH &lt; 7,10 and/or Apgar score ≤ 6 5 minute Following serious adverse reaction adverse event also register immediately electronic medical journal patient : - Intrauterine dead labour - Maternal amniotic fluid emboli thromboembolic event - Maternal cardiac arrest - Maternal Pulmonary edema - Uterine rupture The woman follow least 3-6 hour postpartum ( termination project medicine ) accord current practice delivery ward . The product resume Syntocinon® use reference determine whether Serious Adverse Reaction expect unexpected . Primary investigator nominate deputy go participant medical file 7-30 day postpartum data management Primary investigator ensure relevant information suspect serious unexpected adverse reaction fatal life-threatening record report soon possible competent authority concern , Ethics Committee , case later seven day knowledge case , relevant follow-up information subsequently communicate within additional eight day . Primary investigator report competent authority concern Ethics Committee concern suspect unexpected serious adverse reaction soon possible within maximum 15 day first knowledge .</detailed_description>
	<mesh_term>Oxytocin</mesh_term>
	<criteria>Women stimulate Syntocinon® infusion induction labour ( without cervical prim prostaglandin ) Unable read understand Danish language give inform consent Cervical dilatation &gt; 4 cm Noncephalic presentation Multiple gestation Pathological fetal heart rate pattern ( cardiotocogram , CTG ) Syntocinon® initiation Fetal weight estimation &gt; 4500 g ( clinical ultrasonic ) Subject decline participation Gestational age le 37 complete week Definition : Stimulation Syntocinon® follow Premature Rupture membrane ( PROM ) induction labour cervical change prior start infusion , whereas stimulation Syntocinon PROM follow establishment significant cervical change augmentation .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Active phase labour</keyword>
	<keyword>Discontinuation</keyword>
	<keyword>Caesarean section</keyword>
</DOC>